Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 612 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]
2. Cita con resumen
Wadström H, Frisell T, Askling J, for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. A nationwide cohort study from Sweden. JAMA Intern Med 2017;177:1605-12. [Ref.ID 102143]
3. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
4. Cita con resumen
Anónimo. Vaccin paludique RTS,S/AS01E. Prescrire 2016;36:725-6. [Ref.ID 100886]
7. Cita con resumen
Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]
8. Cita con resumen
McCarthy M. US Senate committee launches investigation into drug pricing. BMJ 2015;351:h5989. [Ref.ID 99683]
9. Cita con resumen
Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]
11.Tiene citas relacionadas
Moorthy VS, Okwo-Bele J-M. Final results from a pivotal phase 3 malaria vaccine trial. Lancet 2015;386:5-7. [Ref.ID 99327]
12. Cita con resumen
Anónimo. Hydroxychloroquine: hypoglycémies. Prescrire 2015;35:18. [Ref.ID 98902]
13. Cita con resumen
Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015;350:h1046. [Ref.ID 98857]
14. Cita con resumen
Goodman JL. Studying “secret serums” — Toward safe, effective Ebola treatments. N Engl J Med 2013;371:1086-9. [Ref.ID 97858]
15. Cita con resumen
Saunders DL, Vanachayangkul P, Lon C, U.S. Army Military Malaria Research Program, National Center for Parasitology Entomology and Malaria Control (CNM), Royal Cambodian Armed Forces. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014;371:484-5. [Ref.ID 97838]
16. Cita con resumen
Gottenberg J-E, Ravaud P, Puéchal X, Le Guem V, Sibila J, Goeb V, Larroche C, Dubost J-J, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zamitsky C, Bataouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014;312:249-58. [Ref.ID 97815]
17. Cita con resumen
Anónimo. Atteintes des ongles d'origine médicamenteuse. Prescrire 2014;34:191-4. [Ref.ID 97362]
18. Cita con resumen
White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet 2014;383:723-35. [Ref.ID 97151]
19.Tiene citas relacionadas Cita con resumen
Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]
20. Cita con resumen
Anónimo. Atteintes de la cornée d'origine médicamenteuse. Prescrire 2013;33:908-13. [Ref.ID 96721]
Seleccionar todas
 
 1 a 20 de 612 siguiente >>